<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04871841</url>
  </required_header>
  <id_info>
    <org_study_id>128/36-21-23</org_study_id>
    <nct_id>NCT04871841</nct_id>
  </id_info>
  <brief_title>Study of Sputnik V COVID-19 Vaccination in Adults in Kazakhstan</brief_title>
  <official_title>Study of Sputnik V COVID-19 Vaccination in Adults in Kazakhstan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karaganda Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karaganda Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety, reactogenicity, and immunogenicity of Gam-COVID-Vac&#xD;
      (Sputnik V) vaccine intended to provide acquired immunity against severe acute respiratory&#xD;
      syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease 2019 (COVID-19). The vaccine&#xD;
      contains two recombinant adenoviral vectors harbouring SARS-CoV-2 Spike gene. The vaccine&#xD;
      will be administered intramuscularly on a 2-dose prime-boost schedule. Participants will be&#xD;
      healthy adults aged greater than or equal to 18 years, voluntarily undergoing vaccination&#xD;
      according to the guidelines of the Ministry of Healthcare of Kazakhstan.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sputnik V (Gam-COVID-Vac) is an adenoviral vector vaccine developed by The Gamaleya Research&#xD;
      Institute of Epidemiology and Microbiology (Moscow, Russia), registered and approved by the&#xD;
      Ministry of Healthcare of Kazakhstan. The vaccine incorporates two recombinant adenoviral&#xD;
      (rAd) vectors, rAd5 and rAd26, harbouring SARS-CoV-2 Spike (S) gene.&#xD;
&#xD;
      Earlier Phase I/II clinical trials established that Sputnik V is safe and efficacious when&#xD;
      given intramuscularly in two sequential doses, as a rAd26-S prime at day 0 followed by rAd5-S&#xD;
      boost at day 21, at 1x10^11 particles per dose. The aim of the current study is to provide&#xD;
      data on the safety, reactogenicity, and immunogenicity of Sputnik V in adults vaccinated in&#xD;
      Kazakhstan using the established vaccination regimen. In addition, the effects of prior&#xD;
      COVID-19 exposure on the vaccine safety, reactogenicity, and immunogenicity will be assessed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 5, 2021</start_date>
  <completion_date type="Anticipated">December 5, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 5, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Solicited Adverse Events (AEs) for 21 Days after First Vaccination</measure>
    <time_frame>day 21</time_frame>
    <description>Solicited AEs are pre-defined local (at the injection site) and systemic adverse events, for which participants are questioned. Solicited local AEs include injection site pain, redness, swelling, itching. Solicited systemic AEs include fatigue, headache, myalgia, chills, fever, joint pain, nausea, vomiting, diarrhea, abdominal pain, rash external to injection site.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Solicited Adverse Events (AEs) for 42 Days after First Vaccination</measure>
    <time_frame>day 42</time_frame>
    <description>Solicited AEs are pre-defined local (at the injection site) and systemic adverse events for which participants are questioned. Solicited local AEs include injection site pain, redness, swelling, itching. Solicited systemic AEs include fatigue, headache, myalgia, chills, fever, joint pain, nausea, vomiting, diarrhea, abdominal pain, rash external to injection site.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the Titres of Systemic SARS-CoV-2 Binding Antibodies</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>The titres of SARS-CoV-2 binding antibodies measured in serum/plasma.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the Titres of Mucosal SARS-CoV-2 Binding Antibodies</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>The titres of SARS-CoV-2 binding antibodies measured in mucosal (nasal) swabs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Titres of Systemic SARS-CoV-2 Neutralizing Antibodies</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>The titres of SARS-CoV-2 neutralizing antibodies measured in serum/plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the titres of Mucosal SARS-CoV-2 Neutralizing Antibodies</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>The titres of SARS-CoV-2 neutralizing antibodies measured in mucosal (nasal) swabs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the concentration of systemic cytokines</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>The levels of cytokines measured in blood plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in the study outcomes between participants with and without prior COVID-19 exposure.</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>The reactogenicity and immunogenicity readouts will be compared between participants with and without prior COVID-19 exposure, as defined by the presence of SARS-CoV-2-reactive antibodies prior to vaccination.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">82</enrollment>
  <condition>Covid19</condition>
  <condition>Vaccine Adverse Reaction</condition>
  <arm_group>
    <arm_group_label>Sputnik V Vaccinees</arm_group_label>
    <description>Participants (healthy adults aged &gt;=18) will receive rAd26-S prime at day 0 and rAd5-S boost at day 21.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sputnik V</intervention_name>
    <description>Participants will receive intramuscular (IM) injection of a single dose of rAd26-S and rAd5-S at day 0 and day 21, respectively.</description>
    <arm_group_label>Sputnik V Vaccinees</arm_group_label>
    <other_name>rAd26-S</other_name>
    <other_name>rAd5-S</other_name>
    <other_name>Gam-COVID-Vac</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants will be recruited by invitation to volunteer at vaccination clinic sites.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant must be healthy (in the physician's clinical judgment and as confirmed by&#xD;
             medical records, and physical examination at screening).&#xD;
&#xD;
          -  Willing to give informed consent, and answer short questionnaires on past exposure to&#xD;
             COVID-19 and post-vaccination reactogenicity.&#xD;
&#xD;
          -  Willing to comply with the requirements of the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant shows signs of an acute illness (excluding minor illnesses such as&#xD;
             diarrhea or mild upper respiratory tract infection).&#xD;
&#xD;
          -  Participant has a positive laboratory-confirmed test result for SARS-CoV-2 infection&#xD;
             at screening.&#xD;
&#xD;
          -  Deemed by investigators to be unlikely to complete study protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Irina Kadyrova, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Centre, Karaganda Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sergey Yegorov, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University, Hamilton, Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anar Turmukhambetova, MD/Doctor of medical science</last_name>
    <role>Study Chair</role>
    <affiliation>Karaganda Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karaganda Medical University</name>
      <address>
        <city>Karaganda</city>
        <zip>100008</zip>
        <country>Kazakhstan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kazakhstan</country>
  </location_countries>
  <reference>
    <citation>Yegorov S, Goremykina M, Ivanova R, Good SV, Babenko D, Shevtsov A, MacDonald KS, Zhunussov Y; COVID-19 Genomics Research Groupon behalf of the Semey COVID-19 Epidemiology Research Group. Epidemiology, clinical characteristics, and virologic features of COVID-19 patients in Kazakhstan: A nation-wide retrospective cohort study. Lancet Reg Health Eur. 2021 May;4:100096. doi: 10.1016/j.lanepe.2021.100096. Epub 2021 Apr 16.</citation>
    <PMID>33880458</PMID>
  </reference>
  <reference>
    <citation>Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Shcheblyakov DV, Dzharullaeva AS, Grousova DM, Erokhova AS, Kovyrshina AV, Botikov AG, Izhaeva FM, Popova O, Ozharovskaya TA, Esmagambetov IB, Favorskaya IA, Zrelkin DI, Voronina DV, Shcherbinin DN, Semikhin AS, Simakova YV, Tokarskaya EA, Lubenets NL, Egorova DA, Shmarov MM, Nikitenko NA, Morozova LF, Smolyarchuk EA, Kryukov EV, Babira VF, Borisevich SV, Naroditsky BS, Gintsburg AL. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020 Sep 26;396(10255):887-897. doi: 10.1016/S0140-6736(20)31866-3. Epub 2020 Sep 4. Erratum in: Lancet. 2021 Jan 9;397(10269):98.</citation>
    <PMID>32896291</PMID>
  </reference>
  <reference>
    <citation>Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, Kovyrshina AV, Lubenets NL, Grousova DM, Erokhova AS, Botikov AG, Izhaeva FM, Popova O, Ozharovskaya TA, Esmagambetov IB, Favorskaya IA, Zrelkin DI, Voronina DV, Shcherbinin DN, Semikhin AS, Simakova YV, Tokarskaya EA, Egorova DA, Shmarov MM, Nikitenko NA, Gushchin VA, Smolyarchuk EA, Zyryanov SK, Borisevich SV, Naroditsky BS, Gintsburg AL; Gam-COVID-Vac Vaccine Trial Group. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021 Feb 20;397(10275):671-681. doi: 10.1016/S0140-6736(21)00234-8. Epub 2021 Feb 2. Erratum in: Lancet. 2021 Feb 20;397(10275):670.</citation>
    <PMID>33545094</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 1, 2021</study_first_submitted>
  <study_first_submitted_qc>May 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2021</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sputnik V</keyword>
  <keyword>Gam-COVID-Vac</keyword>
  <keyword>Vaccine safety</keyword>
  <keyword>Vaccine reactogenicity</keyword>
  <keyword>Vaccine immunogenicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

